VRAYLAR ™

Clinical pharmacology

Initial U.S. Approval: 2015

Mechanism of Action: The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

Indications and usage

INDICATIONS AND USAGE: VRAYLAR™ is indicated for the:
Treatment of schizophrenia.
Acute treatment of manic or mixed episodes associated with bipolar I disorder.

Dosage and administration

Drug UPDATES: VRAYLAR ™ - cariprazine capsule
[Drug information / PDF] Click link for the latest monograph
Dosing: Click (+) next to Dosage and Administration section (drug info link)

How supplied

HOW SUPPLIED:
VRAYLAR (cariprazine) capsules are available in four strengths.

1.5 mg capsules: White cap and body imprinted with "FL 1.5"
3 mg capsules: Green to blue-green cap and white body imprinted with "FL 3"
4.5 mg capsules: Green to blue-green cap and body imprinted with "FL 4.5"
6 mg capsules: Purple cap and white body imprinted with "FL 6"

Reference

[Drug information / PDF] Click link for the latest monograph

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.